报价延迟最少15分钟:2026/05/13 01:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.15 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.11/-0.23
|
|
企业价值
835.72M
|
| 资产负债 |
|
每股账面净值
-0.13
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
5.00M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways. |
